Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 May;67(5):331-7.
doi: 10.1002/iub.1383. Epub 2015 May 19.

RSK3: A regulator of pathological cardiac remodeling

Affiliations
Review

RSK3: A regulator of pathological cardiac remodeling

Eliana C Martinez et al. IUBMB Life. 2015 May.

Abstract

The family of p90 ribosomal S6 kinases (RSKs) are pleiotropic effectors for extracellular signal-regulated kinase signaling pathways. Recently, RSK3 was shown to be important for pathological remodeling of the heart. Although cardiac myocyte hypertrophy can be compensatory for increased wall stress, in chronic heart diseases, this nonmitotic cell growth is usually associated with interstitial fibrosis, increased cell death, and decreased cardiac function. Although RSK3 is less abundant in the cardiac myocyte than other RSK family members, RSK3 appears to serve a unique role in cardiac myocyte stress responses. A potential mechanism conferring the unique function of RSK3 in the heart is anchoring by the scaffold protein muscle A-kinase anchoring protein β (mAKAPβ). Recent findings suggest that RSK3 should be considered as a therapeutic target for the prevention of heart failure, a clinical syndrome of major public health significance.

Keywords: Keywords ribosomal S6 kinase; heart; hypertrophy; mAKAP; remodeling; scaffold; signal transduction.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. RSK3 Structure
Like the related mitogen- and stress-activated kinases (MSK), all four RSKs contain two catalytic domains, N-terminal (NTKD) and C-terminal (CTKD) kinase domains (13). In inactive RSK, the CTKD binds the autoinhibitory domain (AID) α-helix. When activated, ERK pre-bound to the D-domain phosphorylates RSK residues, including the CTKD activation loop (T570). The CTKD then autophosphorylates S377, permitting PDK1 binding and PDK1 phosphorylation of the NTKD activation loop (S218). The NTKD then phosphorylates RSK substrates.
Fig 2
Fig 2. Structures of the Known RSK Inhibitors
Fig. 3
Fig. 3. Model for mAKAPβ-RSK3 Signaling
ERK pathways are activated by stress signaling, including α1-adrenergic receptors (α1-AR). Anchored by the perinuclear scaffold muscle A-kinase anchoring protein (mAKAPβ), RSK3 is an ERK effector that phosphorylates cytosolic and nuclear substrates, contributing to gene expression that promotes pathological remodeling.

References

    1. Go AS, Mozaffarian D, Roger VL, Benjamin EJ, Berry JD, Blaha MJ, Dai S, Ford ES, Fox CS, Franco S, Fullerton HJ, Gillespie C, Hailpern SM, Heit JA, Howard VJ, Huffman MD, Judd SE, Kissela BM, Kittner SJ, Lackland DT, Lichtman JH, Lisabeth LD, Mackey RH, Magid DJ, Marcus GM, Marelli A, Matchar DB, McGuire DK, Mohler ER, 3rd, Moy CS, Mussolino ME, Neumar RW, Nichol G, Pandey DK, Paynter NP, Reeves MJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Wong ND, Woo D, Turner MB, American Heart Association Statistics C. Stroke Statistics S Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014;129:e28–e292. - PMC - PubMed
    1. Braunwald E. Heart failure. JACC Heart failure. 2013;1:1–20. - PubMed
    1. Loffredo FS, Nikolova AP, Pancoast JR, Lee RT. Heart failure with preserved ejection fraction: molecular pathways of the aging myocardium. Circ Res. 2014;115:97–107. - PMC - PubMed
    1. Sharma K, Kass DA. Heart failure with preserved ejection fraction: mechanisms, clinical features, and therapies. Circ Res. 2014;115:79–96. - PMC - PubMed
    1. Finn SG, Dickens M, Fuller SJ. c-Jun N-terminal kinase-interacting protein 1 inhibits gene expression in response to hypertrophic agonists in neonatal rat ventricular myocytes. Biochem J. 2001;358:489–495. - PMC - PubMed

Publication types

MeSH terms

Substances